A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma

NCT06472895 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: AK112 monotherapy

Sponsor

Peking University Cancer Hospital & Institute